Explore more publications!

China vows funding to support HIV prevention in South Africa

(MENAFN) China has committed $3.49 million over two years to support HIV prevention initiatives in South Africa, according to reports. The agreement, coordinated by UNAIDS, was announced at a ceremony held at the Chinese Embassy in Pretoria.

South Africa, home to roughly 8 million people living with HIV and nearly 6 million on antiretroviral therapy, has emphasized reducing new infections, particularly among high-risk groups such as adolescents and young adults.

UNAIDS Executive Director Winnie Byanyima said the funding underscores China’s support for multilateral cooperation and South–South partnerships. "It shows China's commitment to multilateralism and advancing South-South cooperation, through sharing of technology, innovation, and grant funding in our pursuit of universal health coverage and the goal of ending AIDS by 2030," she said.

Chinese Ambassador to South Africa Wu Peng described the project as a tangible step under China’s Global Development Initiative, contributing to the creation of a “global community of health for all.” He added, "China stands firmly with South Africa as it strengthens its HIV prevention and treatment programs. In addition to this project, we stand ready to assist South Africa in establishing a sustainable HIV/AIDS response system through policy dialogue.”

The initiative, spanning two years, is expected to support HIV prevention programs targeting 54,000 adolescents and young people.

MENAFN25112025000045017640ID1110393510


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions